Wed, Feb 21st 2024
Alys Pharmaceuticals, the immuno-dermatology trailblazer with a $100M boost from Medicxi. Unveiling a unique fusion of technology and expertise from renowned scientists like John Harris and Nobel Laureate Craig Mello.
Alys Pharmaceuticals, Inc. (“Alys”) steps into the spotlight as an immuno-dermatology-centric entity. Alys report comes claims:
Their R&D pipeline fueled by their platform of technology and a substantial $100 million backing from Medicxi.
Born from the fusion of six Medicxi asset-centric ventures, Alys presents a dynamic pipeline filled with cutting-edge programs and technologies for various skin conditions.
The inception of Alys is the result of a collaboration between Medicxi, dermatology authorities, and renowned scientists.
This includes John Harris and Nobel Laureate Craig Mello, both hailing from UMass Chan Medical School, Brian Kim from the Icahn School of Medicine at Mount Sinai, and Lars French from LMU Munich, among others.
With an ambitious goal to overhaul the dermatology treatment landscape, Alys is led by co-founder and COO Thibaud Portal, ex-Global Head of Prescription Medicines at Galderma, and Francesco De Rubertis from Medicxi, who chairs the board.
Alys Pharmaceuticals positions itself at the forefront of dermatological innovation, targeting emerging conditions such as atopic dermatitis and chronic spontaneous urticaria for groundbreaking advancements.
The company’s pipeline also prioritizes areas with limited treatment options, including mastocytosis, cutaneous T-cell lymphoma, and the mitigation of oncology therapy-related skin side effects.
Alys is partnered with institutions like Gustave Roussy, Georgia Institute of Technology, Empa, and more. This approach underscores Alys’s dedication to integrating academic and practical research insights.
With over twelve active endeavors, Alys foresees its pipeline expanding organically, driven by its advanced platforms. These platforms span inflammatory and autoimmune disorders, dermatological support for oncology patients, and rare skin diseases.
In the coming three years, Alys aims to achieve over six clinical proof-of-concept readouts and advance at least one program to registration studies.
English 
German 
French 
Spanish 
Arabic